Entero Therapeutics (ENTO) Stock Price, News & Analysis

Company Overview

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Key Stats

• Today's Range: $0.33 to $0.35
• 50-Day Range: $0.34 to $0.61
• 52-Week Range: $0.19 to $3.16
• Volume: 20,125 shs
• Average Volume: 463,147 shs
• Market Capitalization: $1.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Entero Therapeutics Stock Analysis - MarketRank™

Entero Therapeutics scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Entero Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Entero Therapeutics has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.51% of the float of Entero Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Entero Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Entero Therapeutics has recently increased by 262.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Entero Therapeutics does not currently pay a dividend.

Dividend Growth

Entero Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.51% of the float of Entero Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Entero Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Entero Therapeutics has recently increased by 262.02%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.44

News Sentiment

Entero Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Entero Therapeutics this week, compared to 0 articles on an average week.

MarketBeat Follows

Only 2 people have added Entero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Entero Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.49% of the stock of Entero Therapeutics is held by insiders.

Percentage Held by Institutions

Only 12.30% of the stock of Entero Therapeutics is held by institutions.

ENTO Stock Analysis - Frequently Asked Questions

How have ENTO shares performed this year?

Entero Therapeutics' stock was trading at $0.6220 at the beginning of the year. Since then, ENTO stock has decreased by 44.4% and is now trading at $0.3460.
View the best growth stocks for 2025 here.

How do I buy shares of Entero Therapeutics?

Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Entero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include Conduit Pharmaceuticals (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), Elevai Labs (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST).

Company Calendar

• Today: 5/01/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENTO
• Previous Symbol: NASDAQ:ENTO
• CIK: 1604191
• Web: www.enterothera.com
• Phone: 561-589-7020
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-15,800,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -87.06%
• Return on Assets: -12.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.34
• Quick Ratio: 5.34

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.31 per share
• Price / Book: 0.15

Miscellaneous

• Outstanding Shares: 4,766,000
• Free Float: 4,731,000
• Market Cap: $1.65 million
• Optionable: N/A
• Beta: 0.88